Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why
CNR Ibb | back to homepage
CNR Ibb | back to homepage

Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why (199 views)

Gallicchio R, Mastrangelo PA, Nardelli A, Mainenti PP, Colasurdo AP, Landriscina M, Guglielmi G, Storto G

Tumori (ISSN: 0300-8916linking, 0300-8916print), 2019 May 16; N/D: 300891619851376-300891619851376.

Export to BibTeX    Export to EndNote

Paper type: Journal Article,

Impact factor: 1.304, 5-year impact factor: 1.069

Url: Not available.

Keywords: Radium-223, Bone Metastases, Castration-Resistant Prostate Cancer, Multidisciplinary Approach, Rules,

Affiliations:
*** IBB - CNR ***

1 Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture, Italy.
2 Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Napoli, Italy.
3 Dipartimento di Medicina Clinica e Sperimentale, Universita degli Studi di Foggia, Italy.
4 IRCCS "Casa Sollievo della Sofferenza," San Giovanni Rotondo, Italy.


References:
Not available.
Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why

Radium-223 dichloride ((223)Ra) is the first, recently approved, alpha-particle-emitting radiopharmaceutical for the treatment of patients with bone metastases in castration-resistant prostate cancer (CRPC) and no evidence of visceral metastases. We explored MEDLINE, relevant congresses, and websites for data on (223)Ra and prostate cancer therapies, focusing on therapeutic strategies and timing, bone metastases, and diagnostic assessment. (223)Ra represents the only bone-targeting agent that has significantly extended patients' overall survival while reducing pain and symptomatic skeletal events. Unlike other radiopharmaceuticals, such as strontium-89 and samarium-153 EDTMP, (223)Ra (11.4-days half-life) has shown a high biological efficiency mainly due to its short penetration range. These features potentially allow reduced bone marrow toxicity and limit undue exposure. (223)Ra has been validated under the product name Xofigo((R)) by the US Food and Drug Administration and the European Medicines Agency. Patient selection, management, and treatment sequencing is recommended to be discussed in the context of a multidisciplinary environment, including oncology, urology, nuclear medicine, and radiation therapy physicians. No consensus has been achieved regarding the optimal timing and its administration as single agent or in combination with zoledronic acid or chemotherapy, so far. This review aims to provide a rationale for the use of (223)Ra in treating metastases from CRPC, highlighting the crucial role of a multidisciplinary approach, the disputed inclusion and exclusion criteria on the basis of agencies regulations, and the value of diagnostics for therapy assessment.
Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why

▼    Targeting Of Protein-Protein Interactions For Therapeutic Purposes
▼    Targeting Sam-Sam interactions mediated by EphA2 receptor: design and evaluation of peptide inhibitors
Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why

Filter those results▼
Query:  [X]
Options:
   Extended  
   IBB affiliation
 
Authors:  [X]
Paper type:  [X]
Start date:  [X]
End date:  [X]
Site:
[Clear form]
Select the year: 
Other filter: ([btitle,keywords] "Radium-223" OR [btit ...

Sort by:   date ▼▲   title ▲ ▼   journal ▲ ▼   authors ▲ ▼   I.F. ▲ ▼
Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, Durante C, Agate L, Filetti S, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R
* Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience (507 views)
Endocrine (ISSN: 1355-008x, 1355-008xlinking), 2017 Nov 06; 59(1): 90-101.
Impact Factor: 3.179
View    Export to BibTeX    Export to EndNote

Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (494 views)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
View    Export to BibTeX    Export to EndNote

D'Antuono F, Nardelli A, Gallicchio R, Giacomobono S, Venetucci A, Pellegrino T, Leggiadro F, D'Errico N, Gattozzi D, Mainenti PP, Storto G
* Palliative Treatment of Bone Metastases with Sm-153 EDTMP at Pain Onset (343 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View    Export to BibTeX    Export to EndNote

Storto G, Gallicchio R, Pellegrino T, Nardelli A, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (453 views) (PDF 30 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
View    Export to BibTeX    Export to EndNote

Storto G, Pellegrino T, Nardelli A, De Falco T, Castaldi E, Ortosecco G, Capasso E, Erra P, Speranza A, Klain M, Molino L, Di Nuzzo C, Pace L, Salvatore M
* Impact of PET-CT with F-18 Fluoride in Implementing Treatment of Painful Bone Metastases with Sm-153 EDTMP (320 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View    Export to BibTeX    Export to EndNote

Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M
* Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (518 views)
Bone (ISSN: 8756-3282), 2006 Jul; 39(1): 35-41.
Impact Factor: 3.829
View    Export to BibTeX    Export to EndNote

Storto G, Paone G, Klain M, Salvatore B, Capacchione D, Soricelli A, Pace L, Salvatore M
* Hematological Toxicity in Patients with Painful Bone Metastases Treated with Sr-89 and Zoledronic Acid (313 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: N/D-N/D.
Impact Factor: 3.883
View    Export to BibTeX    Export to EndNote

Storto G, Paone G, Ibello F, Klain M, Liuzzi R, Marinelli A, Soricelli A, Pace L, Salvatore M
* Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (406 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2004 Sep; 31: N/D-N/D.
Impact Factor: 3.935
View    Export to BibTeX    Export to EndNote

8 Records (3 excluding Abstracts).
Total impact factor: 29.443 (9.468 excluding Abstracts).
Total 5 year impact factor: 30.985 (9.718 excluding Abstracts).

Last modified by Marco Comerci on Sunday 12 July 2020, 13:14:40
199 views. Last view on Friday 20 September 2024, 20:51:37